{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T22:09:41Z","timestamp":1785276581708,"version":"3.55.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T00:00:00Z","timestamp":1653523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1007\/s10072-022-06131-7","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T08:02:54Z","timestamp":1653552174000},"page":"5189-5199","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Medications on hypertension, hyperlipidemia, diabetes, and risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4046-8439","authenticated-orcid":false,"given":"Nan","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,26]]},"reference":[{"issue":"9769","key":"6131_CR1","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1016\/S0140-6736(10)61156-7","volume":"377","author":"MC Kiernan","year":"2011","unstructured":"Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942\u2013955","journal-title":"Lancet"},{"issue":"4","key":"6131_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/archneur.64.4.522","volume":"64","author":"J Visser","year":"2007","unstructured":"Visser J et al (2007) Disease course and prognostic factors of progressive muscular atrophy. Arch Neurol 64(4):522\u2013528","journal-title":"Arch Neurol"},{"issue":"12","key":"6131_CR3","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1136\/jnnp-2015-312908","volume":"87","author":"JA Knibb","year":"2016","unstructured":"Knibb JA et al (2016) A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry 87(12):1361\u20131367","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"6131_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/WCO.0000000000000730","volume":"32","author":"E Longinetti","year":"2019","unstructured":"Longinetti E, Fang F (2019) Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol 32(5):771\u2013776","journal-title":"Curr Opin Neurol"},{"key":"6131_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neubiorev.2019.12.032","volume":"111","author":"JP Rosa Silva","year":"2020","unstructured":"Rosa Silva JP et al (2020) Quality of life and functional independence in amyotrophic lateral sclerosis: a systematic review. Neurosci Biobehav Rev 111:1\u201311","journal-title":"Neurosci Biobehav Rev"},{"issue":"5","key":"6131_CR6","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1111\/ane.13073","volume":"139","author":"F De Marchi","year":"2019","unstructured":"De Marchi F et al (2019) Depression and risk of cognitive dysfunctions in amyotrophic lateral sclerosis. Acta Neurol Scand 139(5):438\u2013445","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"6131_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1136\/jnnp.2008.163246","volume":"80","author":"MC McElhiney","year":"2009","unstructured":"McElhiney MC et al (2009) Prevalence of fatigue and depression in ALS patients and change over time. J Neurol Neurosurg Psychiatry 80(10):1146\u20131149","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3\u20134","key":"6131_CR8","doi-asserted-by":"publisher","first-page":"265","DOI":"10.3109\/21678421.2014.980428","volume":"16","author":"JG Rabkin","year":"2015","unstructured":"Rabkin JG et al (2015) Depression and wish to die in a multicenter cohort of ALS patients. Amyotroph Lateral Scler Frontotemporal Degener 16(3\u20134):265\u2013273","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1\u20132","key":"6131_CR9","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1080\/21678421.2019.1655060","volume":"21","author":"NJ Thakore","year":"2020","unstructured":"Thakore NJ, Lapin BR, Pioro EP (2020) Stage-specific riluzole effect in amyotrophic lateral sclerosis: a retrospective study. Amyotroph Lateral Scler Frontotemporal Degener 21(1\u20132):140\u2013143","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"6131_CR10","unstructured":"(2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 16(7): 505\u2013512"},{"issue":"3","key":"6131_CR11","first-page":"Cd001447","volume":"2012","author":"RG Miller","year":"2012","unstructured":"Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)\/motor neuron disease (MND). Cochrane Database Syst Rev 2012(3):Cd001447","journal-title":"Cochrane Database Syst Rev"},{"issue":"7\u20138","key":"6131_CR12","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1080\/21678421.2017.1336560","volume":"18","author":"C Moglia","year":"2017","unstructured":"Moglia C et al (2017) Influence of arterial hypertension, type 2 diabetes and cardiovascular risk factors on ALS outcome: a population-based study. Amyotroph Lateral Scler Frontotemporal Degener 18(7\u20138):590\u2013597","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"8","key":"6131_CR13","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/jamaneurol.2015.0910","volume":"72","author":"MA Kioumourtzoglou","year":"2015","unstructured":"Kioumourtzoglou MA et al (2015) Diabetes mellitus, obesity, and diagnosis of amyotrophic lateral sclerosis: a population-based study. JAMA Neurol 72(8):905\u2013911","journal-title":"JAMA Neurol"},{"issue":"2","key":"6131_CR14","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3109\/17482968.2011.610110","volume":"13","author":"C Moreau","year":"2012","unstructured":"Moreau C et al (2012) Modifying effect of arterial hypertension on amyotrophic lateral sclerosis. Amyotroph Lateral Scler 13(2):194\u2013201","journal-title":"Amyotroph Lateral Scler"},{"issue":"6","key":"6131_CR15","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1111\/ene.13620","volume":"25","author":"J Mandrioli","year":"2018","unstructured":"Mandrioli J et al (2018) Cardiovascular diseases may play a negative role in the prognosis of amyotrophic lateral sclerosis. Eur J Neurol 25(6):861\u2013868","journal-title":"Eur J Neurol"},{"key":"6131_CR16","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jocn.2019.05.036","volume":"66","author":"L Lian","year":"2019","unstructured":"Lian L et al (2019) Environmental risk factors and amyotrophic lateral sclerosis (ALS): a case-control study of ALS in China. J Clin Neurosci 66:12\u201318","journal-title":"J Clin Neurosci"},{"issue":"7\u20138","key":"6131_CR17","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1080\/21678421.2018.1511731","volume":"19","author":"DM Freedman","year":"2018","unstructured":"Freedman DM et al (2018) Relationship of statins and other cholesterol-lowering medications and risk of amyotrophic lateral sclerosis in the US elderly. Amyotroph Lateral Scler Frontotemporal Degener 19(7\u20138):538\u2013546","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"10","key":"6131_CR18","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1007\/s00415-014-7445-1","volume":"261","author":"M Seelen","year":"2014","unstructured":"Seelen M et al (2014) Prior medical conditions and the risk of amyotrophic lateral sclerosis. J Neurol 261(10):1949\u20131956","journal-title":"J Neurol"},{"issue":"3","key":"6131_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.3233\/JAD-2009-1155","volume":"18","author":"S Cardoso","year":"2009","unstructured":"Cardoso S et al (2009) Insulin is a two-edged knife on the brain. J Alzheimers Dis 18(3):483\u2013507","journal-title":"J Alzheimers Dis"},{"issue":"3","key":"6131_CR20","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s10571-012-9900-9","volume":"33","author":"H Sun","year":"2013","unstructured":"Sun H et al (2013) Therapeutic potential of N-acetyl-glucagon-like peptide-1 in primary motor neuron cultures derived from non-transgenic and SOD1-G93A ALS mice. Cell Mol Neurobiol 33(3):347\u2013357","journal-title":"Cell Mol Neurobiol"},{"issue":"3\u20134","key":"6131_CR21","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1080\/21678421.2019.1682613","volume":"21","author":"RM Pfeiffer","year":"2020","unstructured":"Pfeiffer RM et al (2020) Identifying potential targets for prevention and treatment of amyotrophic lateral sclerosis based on a screen of medicare prescription drugs. Amyotroph Lateral Scler Frontotemporal Degener 21(3\u20134):235\u2013245","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"15","key":"6131_CR22","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","volume":"283","author":"DF Stroup","year":"2000","unstructured":"Stroup DF et al (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008\u201312","journal-title":"JAMA"},{"key":"6131_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","volume":"339","author":"A Liberati","year":"2009","unstructured":"Liberati A et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700","journal-title":"BMJ"},{"key":"6131_CR24","doi-asserted-by":"crossref","unstructured":"Skajaa N et al (2021) Statin initiation and risk of amyotrophic lateral sclerosis: a Danish population-based cohort study. Epidemiology","DOI":"10.1097\/EDE.0000000000001384"},{"issue":"6","key":"6131_CR25","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1111\/ene.14190","volume":"27","author":"D Mariosa","year":"2020","unstructured":"Mariosa D et al (2020) Antidiabetics, statins and the risk of amyotrophic lateral sclerosis. Eur J Neurol 27(6):1010\u20131016","journal-title":"Eur J Neurol"},{"issue":"1","key":"6131_CR26","volume":"6","author":"G Torrandell-Haro","year":"2020","unstructured":"Torrandell-Haro G et al (2020) Statin therapy and risk of Alzheimer\u2019s and age-related neurodegenerative diseases. Alzheimers Dement (N Y) 6(1):e12108","journal-title":"Alzheimers Dement (N Y)"},{"issue":"8","key":"6131_CR27","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1111\/ene.14300","volume":"27","author":"J Schumacher","year":"2020","unstructured":"Schumacher J et al (2020) Statins, diabetes mellitus and prognosis of amyotrophic lateral sclerosis: data from 501 patients of a population-based registry in southwest Germany. Eur J Neurol 27(8):1405\u20131414","journal-title":"Eur J Neurol"},{"issue":"7","key":"6131_CR28","doi-asserted-by":"publisher","first-page":"2130","DOI":"10.1007\/s00415-020-09799-z","volume":"267","author":"K Diekmann","year":"2020","unstructured":"Diekmann K et al (2020) Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. J Neurol 267(7):2130\u20132141","journal-title":"J Neurol"},{"key":"6131_CR29","doi-asserted-by":"crossref","unstructured":"Bond L et al (2020) Associations of Patient Mood, Modulators of Quality of Life, and Pharmaceuticals with Amyotrophic Lateral Sclerosis Survival Duration. Behav Sci (Basel) 10(1)","DOI":"10.3390\/bs10010033"},{"issue":"5\u20136","key":"6131_CR30","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3109\/21678421.2016.1143515","volume":"17","author":"C Franchi","year":"2016","unstructured":"Franchi C et al (2016) Angiotensin-converting enzyme inhibitors and motor neuron disease: an unconfirmed association. Amyotroph Lateral Scler Frontotemporal Degener 17(5\u20136):385\u2013388","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"1","key":"6131_CR31","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaneurol.2014.3367","volume":"72","author":"FC Lin","year":"2015","unstructured":"Lin FC et al (2015) Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk: a total population-based case-control study. JAMA Neurol 72(1):40\u201348","journal-title":"JAMA Neurol"},{"issue":"6","key":"6131_CR32","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1080\/17482960802163614","volume":"9","author":"M Qureshi","year":"2008","unstructured":"Qureshi M et al (2008) Medications and laboratory parameters as prognostic factors in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 9(6):369\u2013374","journal-title":"Amyotroph Lateral Scler"},{"issue":"5","key":"6131_CR33","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S0924-980X(98)00035-6","volume":"109","author":"D Linden","year":"1998","unstructured":"Linden D, Diehl RR, Berlit P (1998) Reduced baroreflex sensitivity and cardiorespiratory transfer in amyotrophic lateral sclerosis. Electroencephalogr Clin Neurophysiol 109(5):387\u2013390","journal-title":"Electroencephalogr Clin Neurophysiol"},{"issue":"4","key":"6131_CR34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000008180","volume":"43","author":"SN Scelsa","year":"2000","unstructured":"Scelsa SN, Khan I (2000) Blood pressure elevations in riluzole-treated patients with amyotrophic lateral sclerosis. Eur Neurol 43(4):224\u2013227","journal-title":"Eur Neurol"},{"issue":"3","key":"6131_CR35","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1001\/archneur.1991.00530150051017","volume":"48","author":"C Armon","year":"1991","unstructured":"Armon C et al (1991) Antecedent medical diseases in patients with amyotrophic lateral sclerosis. A population-based case-controlled study in Rochester, Minn, 1925 through 1987. Arch Neurol 48(3):283\u20136","journal-title":"Arch Neurol"},{"key":"6131_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117292","volume":"421","author":"M Pereira","year":"2021","unstructured":"Pereira M et al (2021) Cardiovascular comorbidities in amyotrophic lateral sclerosis. J Neurol Sci 421:117292","journal-title":"J Neurol Sci"},{"issue":"4","key":"6131_CR37","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S1474-4422(07)70077-7","volume":"6","author":"PG Kehoe","year":"2007","unstructured":"Kehoe PG, Wilcock GK (2007) Is inhibition of the renin-angiotensin system a new treatment option for Alzheimer\u2019s disease? Lancet Neurol 6(4):373\u2013378","journal-title":"Lancet Neurol"},{"issue":"3","key":"6131_CR38","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1474-4422(11)70015-1","volume":"10","author":"T Philips","year":"2011","unstructured":"Philips T, Robberecht W (2011) Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol 10(3):253\u2013263","journal-title":"Lancet Neurol"},{"issue":"1","key":"6131_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0014-2999(99)00211-3","volume":"373","author":"A Ravati","year":"1999","unstructured":"Ravati A et al (1999) Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and rats. Eur J Pharmacol 373(1):21\u201333","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"6131_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3109\/10715769309111600","volume":"19","author":"ML Mira","year":"1993","unstructured":"Mira ML et al (1993) Angiotensin converting enzyme inhibitors as oxygen free radical scavengers. Free Radic Res Commun 19(3):173\u2013181","journal-title":"Free Radic Res Commun"},{"issue":"3","key":"6131_CR41","first-page":"367","volume":"21","author":"G Sengul","year":"2011","unstructured":"Sengul G et al (2011) Neuroprotective effect of ACE inhibitors in glutamate - induced neurotoxicity: rat neuron culture study. Turk Neurosurg 21(3):367\u2013371","journal-title":"Turk Neurosurg"},{"issue":"6","key":"6131_CR42","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1093\/aje\/kwq416","volume":"173","author":"H Wang","year":"2011","unstructured":"Wang H et al (2011) Vitamin E intake and risk of amyotrophic lateral sclerosis: a pooled analysis of data from 5 prospective cohort studies. Am J Epidemiol 173(6):595\u2013602","journal-title":"Am J Epidemiol"},{"issue":"7","key":"6131_CR43","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1212\/01.WNL.0000140705.23869.E9","volume":"63","author":"T Ohrui","year":"2004","unstructured":"Ohrui T et al (2004) Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 63(7):1324\u20131325","journal-title":"Neurology"},{"issue":"1","key":"6131_CR44","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/j.1445-5994.2000.tb01054.x","volume":"30","author":"KA Reardon","year":"2000","unstructured":"Reardon KA et al (2000) The angiotensin converting enzyme (ACE) inhibitor, perindopril, modifies the clinical features of Parkinson\u2019s disease. Aust N Z J Med 30(1):48\u201353","journal-title":"Aust N Z J Med"},{"key":"6131_CR45","doi-asserted-by":"crossref","unstructured":"Lin SY et al (2020) Effects of \u03b2-adrenergic blockade on metabolic and inflammatory responses in a rat model of ischemic stroke. Cells 9(6)","DOI":"10.3390\/cells9061373"},{"key":"6131_CR46","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3389\/fncel.2015.00225","volume":"9","author":"SS Leal","year":"2015","unstructured":"Leal SS, Gomes CM (2015) Calcium dysregulation links ALS defective proteins and motor neuron selective vulnerability. Front Cell Neurosci 9:225","journal-title":"Front Cell Neurosci"},{"issue":"2","key":"6131_CR47","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/0960-8966(95)00024-0","volume":"6","author":"RG Miller","year":"1996","unstructured":"Miller RG et al (1996) Controlled trial of nimodipine in amyotrophic lateral sclerosis. Neuromuscul Disord 6(2):101\u2013104","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"6131_CR48","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/mus.880190405","volume":"19","author":"RG Miller","year":"1996","unstructured":"Miller RG et al (1996) A clinical trial of verapamil in amyotrophic lateral sclerosis. Muscle Nerve 19(4):511\u2013515","journal-title":"Muscle Nerve"},{"issue":"4","key":"6131_CR49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s00415-010-5805-z","volume":"258","author":"J Dorst","year":"2011","unstructured":"Dorst J et al (2011) Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol 258(4):613\u2013617","journal-title":"J Neurol"},{"issue":"13","key":"6131_CR50","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1212\/01.wnl.0000285080.70324.27","volume":"70","author":"L Dupuis","year":"2008","unstructured":"Dupuis L et al (2008) Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology 70(13):1004\u20131009","journal-title":"Neurology"},{"issue":"5\u20136","key":"6131_CR51","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3109\/21678421.2015.1047454","volume":"16","author":"R Huang","year":"2015","unstructured":"Huang R et al (2015) The serum lipid profiles of amyotrophic lateral sclerosis patients: a study from south-west China and a meta-analysis. Amyotroph Lateral Scler Frontotemporal Degener 16(5\u20136):359\u2013365","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"issue":"4","key":"6131_CR52","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1002\/ana.25431","volume":"85","author":"S Bandres-Ciga","year":"2019","unstructured":"Bandres-Ciga S et al (2019) Shared polygenic risk and causal inferences in amyotrophic lateral sclerosis. Ann Neurol 85(4):470\u2013481","journal-title":"Ann Neurol"},{"issue":"3","key":"6131_CR53","first-page":"Ra73","volume":"16","author":"J Beltowski","year":"2010","unstructured":"Beltowski J (2010) Statins and ALS: the possible role of impaired LXR signaling. Med Sci Monit 16(3):Ra73-78","journal-title":"Med Sci Monit"},{"issue":"6","key":"6131_CR54","doi-asserted-by":"publisher","first-page":"515","DOI":"10.2165\/00002018-200730060-00005","volume":"30","author":"IR Edwards","year":"2007","unstructured":"Edwards IR, Star K, Kiuru A (2007) Statins, neuromuscular degenerative disease and an amyotrophic lateral sclerosis-like syndrome: an analysis of individual case safety reports from vigibase. Drug Saf 30(6):515\u2013525","journal-title":"Drug Saf"},{"key":"6131_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106248","volume":"199","author":"T Wannarong","year":"2020","unstructured":"Wannarong T, Ungprasert P (2020) Diabetes mellitus is associated with a lower risk of amyotrophic lateral sclerosis: a systematic review and meta-analysis. Clin Neurol Neurosurg 199:106248","journal-title":"Clin Neurol Neurosurg"},{"issue":"4","key":"6131_CR56","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s10072-021-05099-0","volume":"42","author":"R Vasta","year":"2021","unstructured":"Vasta R et al (2021) The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurol Sci 42(4):1377\u20131387","journal-title":"Neurol Sci"},{"issue":"1","key":"6131_CR57","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1038\/s41598-022-06463-6","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L et al (2022) Association between type 2 diabetes and amyotrophic lateral sclerosis. Sci Rep 12(1):2544","journal-title":"Sci Rep"},{"issue":"31","key":"6131_CR58","doi-asserted-by":"publisher","first-page":"18591","DOI":"10.1073\/pnas.2005748117","volume":"117","author":"T Zu","year":"2020","unstructured":"Zu T et al (2020) Metformin inhibits RAN translation through PKR pathway and mitigates disease in C9orf72 ALS\/FTD mice. Proc Natl Acad Sci U S A 117(31):18591\u201318599","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"6131_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0193031","volume":"13","author":"J Han","year":"2018","unstructured":"Han J et al (2018) Metformin suppresses retinal angiogenesis and inflammation in vitro and in vivo. PLoS ONE 13(3):e0193031","journal-title":"PLoS ONE"},{"issue":"11","key":"6131_CR60","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1111\/ene.12632","volume":"22","author":"D Mariosa","year":"2015","unstructured":"Mariosa D et al (2015) Association between diabetes and amyotrophic lateral sclerosis in Sweden. Eur J Neurol 22(11):1436\u20131442","journal-title":"Eur J Neurol"},{"issue":"9","key":"6131_CR61","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1172\/JCI124481","volume":"129","author":"K Araki","year":"2019","unstructured":"Araki K et al (2019) TDP-43 regulates early-phase insulin secretion via CaV1.2-mediated exocytosis in islets. J Clin Invest 129(9):3578\u20133593","journal-title":"J Clin Invest"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-022-06131-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-022-06131-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T04:09:17Z","timestamp":1660709357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-022-06131-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,26]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["6131"],"URL":"https:\/\/doi.org\/10.1007\/s10072-022-06131-7","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,26]]},"assertion":[{"value":"7 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval and consent to participate were not necessary for this systematic review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}